Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practice.

Glatzer, Markus; Faivre-Finn, Corinne; De Ruysscher, Dirk; Widder, Joachim; Van Houtte, Paul; Troost, Esther G C; Dahele, M R; Slotman, Ben J; Ramella, Sara; Pöttgen, Christoph; Peeters, Stephanie T H; Nestle, Ursula; McDonald, Fiona; Le Pechoux, Cecile; Dziadziuszko, Rafal; Belderbos, José; Putora, Paul M. (2020). Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practice. (In Press). Radiotherapy and oncology, 150, pp. 26-29. Elsevier 10.1016/j.radonc.2020.05.004

[img] Text
1-s2.0-S0167814020302462-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (530kB) | Request a copy

BACKGROUND In limited disease small cell lung cancer (LD-SCLC), the CONVERT trial has not demonstrated superiority of once-daily (QD) radiotherapy (66 Gy) over twice-daily (BID) radiotherapy (45 Gy). We explored the factors influencing the selection between QD and BID regimens. METHODS Thirteen experienced European thoracic radiation oncologists as selected by the European Society for Therapeutic Radiation Oncology (ESTRO) were asked to describe their strategies in the management of LD-SCLC. Treatment strategies were subsequently converted into decision trees and analysed for agreement and discrepancies. RESULTS Logistic reasons, patientś performance status and radiotherapy dose constraints were the three major decision criteria used by most experts in decision making. The use of QD and BID regimens was balanced among European experts, but there was a trend towards the BID regimen for fit patients able to travel twice a day to the radiotherapy site. CONCLUSION BID and QD radiotherapy are both accepted regimens among experts and the decision is influenced by pragmatic factors such as availability of transportation.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Glatzer, Markus and Putora, Paul Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0167-8140

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

30 Jun 2020 17:18

Last Modified:

02 Jul 2020 06:27

Publisher DOI:

10.1016/j.radonc.2020.05.004

PubMed ID:

32447035

Uncontrolled Keywords:

BID radiotherapy QD radiotherapy SCLC decision making limited disease small cell lung cancer

BORIS DOI:

10.7892/boris.144504

URI:

https://boris.unibe.ch/id/eprint/144504

Actions (login required)

Edit item Edit item
Provide Feedback